Literature DB >> 11153083

Construction, biological activity, and immunogenicity of synthetic envelope DNA vaccines based on a primary, CCR5-tropic, early HIV type 1 isolate (BX08) with human codons.

S Corbet1, L Vinner, D M Hougaard, K Bryder, H V Nielsen, C Nielsen, A Fomsgaard.   

Abstract

So far codon-optimized HIV-1 envelope genes have been investigated for the T cell line-adapted strain MN, which differs in several aspects from primary isolates. Envelopes of primary isolates may be more relevant for vaccine purposes. This article describes for the first time the engineering and characterization of four "humanized" genes encoding the secreted gp120/gp140, or the membrane-bound gp150/gp160, of a primary CCR5 tropic, clade B, clinical isolate HIV-1(BX08). The genes were built in fragments for easy cassette exchange of regions important for immunogenicity, function, and expression. The transcription and expression of the synthetic genes in mammalian cell lines were Rev independent and highly increased. Increased expression of membrane-bound gp160 induced a high cytopathic effect in U87.CD4.CCR5 cells. Gene gun and intramuscular DNA vaccination in mice induced a strong specific cytotoxic T lymphocyte response independent of the gene construct, expression level, or DNA immunization route. In contrast, the highest anti-gp120 antibody levels were induced by synthetic genes encoding the secreted glycoproteins followed by gp160/gp150. Unlike HIV-1(MN), HIV-1(BX08) V3 was not immune dominant. Despite the high antibody response only low and inconsistent neutralizing titers to the homologous HIV-1 isolate were measured. However, neutralization of SHIV89.6P could be obtained. Thus, the neutralizing epitopes on the cell line-adapted SHIV89.6P and HIV-1(MN) may be more antigenically available for the cross-neutralizing antibodies induced. In conclusion, complete "humanization" of the DNA vaccine genes failed to induce a consistent neutralizing antibody response, albeit expression and immunogenicity of the primary HIV-1 glycoproteins were greatly improved. Optimization in terms of improving neutralization may require further modifications of the DNA vaccine gene. The synthetic cassette construct described is a convenient tool developed to investigate this further.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11153083     DOI: 10.1089/088922200750054738

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  10 in total

1.  Increased humoral immunity by DNA vaccination using an α-tocopherol-based adjuvant.

Authors:  Ingrid Karlsson; Marie Borggren; Jens Nielsen; Dennis Christensen; Jim Williams; Anders Fomsgaard
Journal:  Hum Vaccin Immunother       Date:  2017-06-14       Impact factor: 3.452

2.  Vector optimization and needle-free intradermal application of a broadly protective polyvalent influenza A DNA vaccine for pigs and humans.

Authors:  Marie Borggren; Jens Nielsen; Karoline Bragstad; Ingrid Karlsson; Jesper S Krog; James A Williams; Anders Fomsgaard
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

3.  Neutralizing Antibody Response and Antibody-Dependent Cellular Cytotoxicity in HIV-1-Infected Individuals from Guinea-Bissau and Denmark.

Authors:  Marie Borggren; Sanne Skov Jensen; Leo Heyndrickx; Angelica A Palm; Jan Gerstoft; Gitte Kronborg; Bo Langhoff Hønge; Sanne Jespersen; Zacarias José da Silva; Ingrid Karlsson; Anders Fomsgaard
Journal:  AIDS Res Hum Retroviruses       Date:  2016-01-07       Impact factor: 2.205

4.  C3d enhances immune responses using low doses of DNA expressing the HIV-1 envelope from codon-optimized gene sequences.

Authors:  Joseph F Bower; Kelly L Sanders; Ted M Ross
Journal:  Curr HIV Res       Date:  2005-04       Impact factor: 1.581

5.  Codon optimization of the tat antigen of human immunodeficiency virus type 1 generates strong immune responses in mice following genetic immunization.

Authors:  Lakshmi Ramakrishna; Krishnamurthy Kumar Anand; Kumarasamypet M Mohankumar; Udaykumar Ranga
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

6.  Boosting of HIV-1 neutralizing antibody responses by a distally related retroviral envelope protein.

Authors:  Hannes Uchtenhagen; Torben Schiffner; Emma Bowles; Leo Heyndrickx; Celia LaBranche; Steven E Applequist; Marianne Jansson; Thushan De Silva; Jaap Willem Back; Adnane Achour; Gabriella Scarlatti; Anders Fomsgaard; David Montefiori; Guillaume Stewart-Jones; Anna-Lena Spetz
Journal:  J Immunol       Date:  2014-05-14       Impact factor: 5.422

7.  Selected HIV-1 Env trimeric formulations act as potent immunogens in a rabbit vaccination model.

Authors:  Leo Heyndrickx; Guillaume Stewart-Jones; Marianne Jansson; Hanneke Schuitemaker; Emma Bowles; Luigi Buonaguro; Berit Grevstad; Lasse Vinner; Katleen Vereecken; Joe Parker; Meghna Ramaswamy; Priscilla Biswas; Guido Vanham; Gabriella Scarlatti; Anders Fomsgaard
Journal:  PLoS One       Date:  2013-09-02       Impact factor: 3.240

8.  Immunological analysis of a Lactococcus lactis-based DNA vaccine expressing HIV gp120.

Authors:  Gregers J Gram; Anders Fomsgaard; Mette Thorn; Søren M Madsen; Jacob Glenting
Journal:  Genet Vaccines Ther       Date:  2007-01-29

9.  Pandemic influenza 1918 H1N1 and 1968 H3N2 DNA vaccines induce cross-reactive immunity in ferrets against infection with viruses drifted for decades.

Authors:  Karoline Bragstad; Cyril J Martel; Joakim S Thomsen; Kim L Jensen; Lars P Nielsen; Bent Aasted; Anders Fomsgaard
Journal:  Influenza Other Respir Viruses       Date:  2010-11-03       Impact factor: 4.380

10.  Optimization of HIV-1 Envelope DNA Vaccine Candidates within Three Different Animal Models, Guinea Pigs, Rabbits and Cynomolgus Macaques.

Authors:  Marie Borggren; Lasse Vinner; Betina Skovgaard Andresen; Berit Grevstad; Johanna Repits; Mark Melchers; Tara Laura Elvang; Rogier W Sanders; Frédéric Martinon; Nathalie Dereuddre-Bosquet; Emma Joanne Bowles; Guillaume Stewart-Jones; Priscilla Biswas; Gabriella Scarlatti; Marianne Jansson; Leo Heyndrickx; Roger Le Grand; Anders Fomsgaard
Journal:  Vaccines (Basel)       Date:  2013-07-19
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.